Drugs / Remifemin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03339882 | Jan → Nov 2017 | — | Zhejiang Cancer Hospital | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remifemin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03339882 ↗ |
| Route | Oral | “Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment” NCT03339882 ↗ |